A Prospective Study of Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: The Keystone-001 Trial

Background and Research Motivation Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive cancer, especially in locally advanced stages. Traditional neoadjuvant chemoradiotherapy (NCRT) is the standard treatment method for this type of cancer. Despite its significant therapeutic effects, local recurrence and distant metastasis rates remai...

Plasma Proteome-Based Test for First-line Treatment Selection in Metastatic Non–Small Cell Lung Cancer

In the tumor microenvironment (Tumor Microenvironment, TME), Immune Checkpoint Inhibitors (ICIs) targeting PD-1 or PD-L1 enhance the body’s natural ability to eliminate cancer cells by disrupting the inhibitory receptor-ligand interaction. However, even so, critical trials indicate that the response rate for monotherapy is <50%, with a median Progr...